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Abstract
Background France is one of the European countries that
spend the most on oncology drugs. To keep pharmaceutical
expenditure under control, Health Authorities highly scruti-
nize market access of costly medicines.
Objective To assess current and future trends in French health
technology assessment (HTA) of antineoplastic drugs indicat-
ed in the treatment of solid tumours.
Methods A review of the SMR and ASMR drivers of the
Transparency Committee (CT) opinions issued for antineo-
plastic drugs indicated in the treatment of solid tumours and
approved between 2009 and 2014 was performed to assess
current trends in French health technology assessment
(HTA), complemented by an expert board consultation to cap-
ture the critical issues on the future of antineoplastic drugs
HTA.
Results Thirty-one drugs indicated for the treatment of solid
tumours were identified (77 % targeted therapies). Initial CT
assessments were available for 26 drugs. Four key items in the
CT assessment were identified: 1) Clinical trial methodology;
2) Acceptance of progression-free survival (PFS) as a valuable
endpoint; 3) Transferability of clinical trials in clinical prac-
tice; 4) Unpredictability of CT decisions. Experts raised the
important development of personalisedmedicines in oncology
and key challenges for oncology products to generate infor-
mation expected from HTA perspective.
Conclusion The French system remains committed to its
values and philosophy (access of all innovations for everybody)
which are threatened by the increasing launch of innovative
therapies and budget constraint. Both HTA decision framework
evolution and revision of the current pricing process should be
considered in France to cope with these new challenges.
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Key Points
The French system remains committed to its values and philosophy
(access of all innovations for everybody) which are threatened by the
increasing launch of innovative therapies and budget constraint.
French HTA analysis decision model will have to evolve to cope with 
the new challenges raised by oncology drugs.
More coordination is expected between European regulators, payers 
and pharma ceutical companies for evidence generation.
1 Introduction
Cancer is a public health issue that affects 3 million people
aged 15 years and over in France with approximately 355,000
new cases and 148,000 cancer-related deaths in 2012 [1].
Over the period between 2005 and 2009, cancer was the first
cause of deaths in men and the second cause of deaths in
women [2], with 33 % and 24 % attributed deaths, respective-
ly [1]. Among all cancers, solid tumours (main solid cancers
include: prostate, testis, breast, bladder, uterine body, uterine
cervix, ovary, pancreas, kidney, lip/oral cavity/pharynx, lar-
ynx, melanoma, liver, lung, thyroid, oesophagus, stomach,
colon-rectum, central nervous system) account for approxi-
mately 83 % of all cancers and caused around 68 % of all
cancer-related deaths in 2012 [3]. The four main cancers are
prostate cancer, breast cancer, colorectal cancer and lung can-
cer [1].
Cancer imposes an enormous financial burden to society,
estimated in France at €17 billion and the cancer-related
healthcare cost was estimated at €7 billion, i.e. 3 % of the total
health-care expenditure [4]. Drug costs represented around
43 % of cancer-related healthcare costs (around €3 billion),
making France one of the EU countries that spends the most
on oncology drugs. The mean cancer drug cost per inhabitant
was estimated at €47 in France, whereas it represented €27 in
Italy, €33 in Germany and Spain, €17 in UK and €28 in EU27
[4].
The high prices of antineoplastic drugs opened debates
among French Health Authorities, scientific and public com-
munity; oncology was pointed at as a therapeutic area raising
economic and ethical concerns. Moreover, these debates have
been widely covered by media [5–19]. In the third national
Cancer Plan (2014-2019) [20], three key actions related to
antineoplastic drugs are planned to reshape assessment criteria
of anticancer drugs, to enhance better use of anticancer drugs,
and to develop horizon scanning to ensure sustainable access
to innovative therapies on the long term.
As part of an effort to confront the deficit of the National
Health Insurance and press it to recover a healthy financial
balance, the successive annual social security funding laws
implemented since 1996 in France provided measures to con-
tain drug expenditure such as price cuts, generic incentives
and additional taxes for pharmaceutical companies [21].
Among these measures, one important change in the French
market access environment was the introduction of health
economic evaluations (Social Security Funding Law for
2012 [22]). Moreover, recent measures showed higher scruti-
ny of Health Authorities on market access pathways for po-
tentially costly medicines, targeting the early access scheme
for innovative medicines (Autorisation Temporaire d’-
Utilisation, ATU) [23, 24], or the funding pathway of costly
medicines on top of Diagnosis Related Groups (DRG) tariffs
known as BListe en sus^ system [16, 24–27].
In France, the assessment of drugs is carried out by the
Transparency Committee (Commission de la Transparence-
CT), which is one of the scientific committees of the French
National Authority for Health (Haute Autorité de Santé, HAS).
This Committee evaluates the newmedicines for which there is
a request for inclusion on a positive list of reimbursed products
and issues opinions based essentially on the review of the med-
ical evidence available. The CT is in charge of assessing the
Actual Benefit (Service Médical Rendu, SMR) and the Im-
provement in Actual Benefit (Amélioration du Service Médical
Rendu, ASMR) of the new medicines. The SMR is set based on
the severity of the disease, the efficacy and safety, the position
of the treatment in the therapeutic strategy, the impact on public
health and type of treatment (preventive, curative or symptom-
atic). The ASMR is set based on the assessment versus relevant
comparators by indication and/or therapeutic strategy. Drug
price setting is established by the Economic Committee on
Healthcare Products (Comité Economique des Produits de
Santé, CEPS) after negotiation with the drug company. ASMR
is one of the key items taken into account during price setting.
The reimbursement rate is fixed by a decision of the National
Healthcare Insurances (Union Nationale des Caisses d’-
Assurance Maladie, UNCAM) based on SMR. The Health
Ministry makes the final decision regarding whether or not
the drug will be registered on the list of reimbursable medi-
cines. This registration is valid for 5 years. At the end of this
period or at any time when significant new information be-
comes available, the CT re-evaluates the SMR and ASMR
levels. For drugs that are likely to have a significant impact
on the health insurance budget or for those claiming an ASMR
I, II or III, health economic assessment is required and is per-
formed by the Economic and Public Health Assessment Com-
mittee (Commission Evaluation Economique et de Santé
Publique, CEESP).
Over the past few years, a shift has been seen in the appre-
ciation of Actual Benefit (Service Médical Rendu, SMR) and
the Improvement in Actual Benefit (Amélioration du Service
Médical Rendu, ASMR) by the Transparency Committee
(Commission de la Transparence, CT). In the evaluation of
the SMR, the CT requires more and more evidence on the
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drug efficacy while the criterion severity of the disease is less
considered. In the evaluation of the ASMR, the CT is increas-
ingly considering the effect size [28]. Of note, head-to-head
trials were stated in the Law n°2011-2012 related to the rein-
forcement of the health safety of drugs and health products as
required to get reimbursement when reference treatment is
available in France (application decree still pending) [23].
In the past, cancer was perceived as a lethal disease with
limited treatment options and oncology area enjoyed from a
relatively lenient pricing and reimbursement environment
compared to other therapeutic areas (e.g. straight acceptance
of non-comparative single arm trials, surrogate endpoints by
health technology assessment agencies).
This study aims to conduct a review of the SMR and
ASMR drivers of the CT opinions of antineoplastic drugs
indicated for the treatment of solid tumours approved in the
last 6 years to assess current trends in French health technol-
ogy assessment (HTA), to confront experts with the outcomes
of this review and discuss the foreseen challenges for HTA of
future antineoplastic medicines in France.
2 Methods
A review of the CTopinions issued for all antineoplastic drugs
indicated in the treatment of solid tumours and approved over
the last 6 years (2009-2014) was performed (cut-off date: 24
February 2015). The secondary research was complemented
by an expert board consultation to capture the critical issues on
the future of antineoplastic drugs’ HTA.
2.1 Drug Selection and Review of the CT Opinions
We used the European Medicines Agency (EMA) website to
identify medicines having a centralized marketing authoriza-
tion (MA) between 2009 and 2014. All drugs approved before
2009 and for which there has been an extension of indication
during the period of interest, as well as generics and
biosimilars were excluded from our search.
We identified all drugs indicated in the treatment of solid
tumours and we extracted from the HAS website the related
CT opinions, including re-assessment, and extensions of indi-
cations opinions. The collected data were compiled into an
extraction grid (Fig. S1 in supplementary file).
Based on the extraction, descriptive statistics and qualita-
tive analysis were performed. Products that were scored
ASMR I, II, III were considered as presenting an additional
benefit acknowledged by the CT. Particular attention was paid
to the rationale for acknowledging an additional benefit. We
randomly looked over the CT opinions in a group of 5 in an
iterative way. We identified and grouped according to similar-
ities the reasons for acknowledging or not the additional
benefit.
Data were extracted by a researcher experienced in extrac-
tion of HTA reports and a quality control was performed by a
research manager experienced in reviewing HTA reports in
oncology and having a long experience of CT processes and
opinions. For qualitative analysis, we believed this methodol-
ogy allows well for controlling the risk of errors.
2.2 Expert Board Meeting
Five experts with significant experience in HTA decision
making in oncology (Fig. S2 in supplementary file) were re-
cruited to participate in a board meeting to review the CT
opinions extraction and provide their insights on oncology
HTA trends in France. The expert board aimed to inform the
opinions of the CT as the process is deliberative and facts
needed to be put in their context. Moreover, as HTA is an
extremely dynamic field, the experts were requested to elab-
orate on the future of HTA of oncology solid tumour products.
A pre-meeting questionnaire based on the findings of the
CTopinions reviewwas sent to the experts and filled in before
the board meeting to prepare and optimize interactions. The
questionnaire was structured around eight sections: general
considerations in HTA trends, clinical trial methodology,
transferability of clinical trial data to clinical practice, clinical
trial efficacy data, specificities of antineoplastic drugs (indica-
tion, targeted therapies, route of administration), health eco-
nomics assessment, price of antineoplastic drugs, as well as
any additional comments the expert would make. A copy of
the questionnaire is available from the authors upon request.
The completed questionnaires received from the experts were
consolidated in a presentation for the meeting.
The board meeting took place over half a day and was
moderated by an expert in HTA and oncology. The meeting
was structured around the key themes identified through the
answers of the experts to the pre-meeting questionnaire as well
as the CT opinions review outcomes.
3 Results
3.1 Selection of Drugs Through EMAWebsite
The search through the EMAwebsite retrieved 297 new treat-
ments that were granted a MA between 2009 and 2014. Of
these, 53 were oncology drugs with 31 indicated for the treat-
ment of solid tumours (Fig. 1, Table 1).
From the selected antineoplastic drugs targeting solid can-
cers, 26 drugs were granted a standard MA and five drugs
were approved under conditional approval (one conditional
MA switched then to standard MA). Four drugs of these 31
drugs were granted an orphan drug status and 19 drugs had an
ATU.
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The main characteristics of the selected drugs are presented
in Fig. 2. Two drugs were indicated in different types of cancer
and three drugs had more than one indication for the same
type of cancer. With a total of six drugs, prostate cancer was
the most frequent indication. Oral route (55 %) was the most
frequent, followed by intravenous route (38 %). Targeted ther-
apies represented 77 % of all drugs.
3.2 Review of CT Opinions
Initial CT assessments were available for 26 drugs. About
35 % of these drugs were indicated as first-line therapies only,
other drugs being indicated as first-line and second-line ther-
apies, as second-line therapies or beyond. Four drugs had an
extension of indication on the considered period with avail-
able CT opinions. Six medicines went through CT re-
assessments (Fig. 1, Table 2).
The average period between MA and the CT opinion was
6.3 months (range: 2; 20) and 7.7 months (range: 2; 33) be-
tween the CT opinion and the price publication. Nineteen
drugs went through an ATUwith a start date available for nine
of them. Time between ATU and MA was 24.2 months in
average (range: 1; 106).
ASMR and SMR ratings were reported in Table 2 and
Fig. 3. Two of the three drugs re-assessed by the CT were
granted a better score. Cabazitaxel was granted an ASMR III
(2012) versus ASMR IV (2011) following new data provided
by the company and considering that cabazitaxel was not dif-
ferent from recently approved therapy in the same indication
which was granted an ASMR III 1. Pazopanib was granted a
lower SMR in one subgroup of patients, with an ASMRV in
this subgroup (2013).
ATU status did not impact the ASMR score (Fig. 4).
Efficacy (effect size)/safety ratio as assessed by the CT
(low, moderate or high) generally predicted SMR ratings
(i.e. a substantial SMR was always correlated with high
efficacy/safety ratio while a moderate, low or insufficient
SMR was correlated with moderate or low efficacy/safety ra-
tio), but not ASMR ratings (Fig. 5).
Fig. 1 Drug selection results
1 Abiraterone acetate had been assessed by the CT in a similar indication
following initial assessment of cabazitaxel and granted ASMR III. Con-
sidering initial resistance data for hormone therapy with abiraterone ace-
tate observed in some patients and new submitted data, the therapeutic
benefit of cabazitaxel was considered to be of the same order as that of
abiraterone acetate.
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3.3 Qualitative Analysis of CTAssessment
The qualitative analysis of the CT opinions allowed identify-
ing four key items of importance in the CTassessment: 1) The
clinical trial methodology; 2) The acceptance of the
progression-free survival (PFS) as a valuable endpoint, while
overall survival remains a key endpoint; 3) The transferability
of clinical trials in clinical practice; 4) The unpredictability of
CT decisions.
On top of that, the targeted specificity of the drug was
considered by the CT for ASMR score granting. For example,
the targeted specificity of vemurafenib, indicated in well-
defined population BRAF V600 mutation-positive
unresectable or metastatic melanoma, was one criteria consid-
ered by the CT in the decision of awarding an ASMR III in
2012.
3.3.1 Importance of Clinical Trial Methodology
The conduct of a clinical trial versus active comparator, when
available, is an important criterion for the CT. For example, in
2011, the CT attributed an insufficient SMR to pazopanib,
indicated in advanced renal cell carcinoma, due to absence
of any direct comparison against the already available medic-
inal products. The clinical data submitted were based on one
pivotal placebo-controlled study and one indirect comparison.
The indirect comparison was considered as uninformative by
the CT because of wide confidence intervals, poor indirect
comparison network, heterogeneity not really assessable and
source information based on intermediate analysis, potentially
biased.
However, the CT may be flexible when there are no thera-
peutic alternatives. For example, vismodegib, indicated in
Table 1 List of selected drugs
indicated in solid tumours INN Brand name MA date Tumour type
Abiraterone acetate Zytiga® 05/09/2011 Prostate
Afatinib Giotrif® 25/09/2013 Lung
Aflibercept Zaltrap® 01/02/2013 Colorectal tract
Axitinib Inlyta® 03/09/2012 Kidney
Cabazitaxel Jevtana® 17/03/2011 Prostate
Cabozantinib Cometriq® 21/03/2014 Thyroid
Catumaxomab Removab® 20/04/2009 Ascites
Crizotinib Xalkori® 23/10/2012 Lung
Dabrafenib Tafinlar® 26/08/2013 Skin
Degarelix Firmagon® 17/02/2009 Prostate
Enzalutamide Xtandi® 21/06/2013 Prostate
Eribulin Halaven® 17/03/2011 Breast
Everolimus Afinitor® 03/08/2009 Breast, pancreas and kidney
Gefitinib Iressa® 24/06/2009 Lung
Ipilimumab Yervoy® 13/07/2011 Skin
Mifamurtide Mepact® 06/03/2009 Bones
Nintedanib Vargatef® 21/11/2014 Lung
Olaparib Lynparza® 16/12/2014 Ovaries, fallopian tubes and peritonea
Pazopanib Votrient® 14/06/2010 Kidney and soft-tissue
Pertuzumab Perjeta® 04/03/2013 Breast
Radium Ra223 dichloride Xofigo® 13/11/2013 Prostate
Ramucirumab Cyramza® 19/12/2014 Gastro-oesophageal tract
Regorafenib Stivarga® 26/08/2013 Colorectal tract
Sipuleucel-T Provenge® 06/09/2013 Prostate
Tegafur/Gimeracil/Oteracil Teysuno® 14/03/2011 Gastro-oesophageal tract
Trametinib Mekinist® 30/06/2014 Skin
Trastuzumab emtansine Kadcyla® 15/11/2013 Breast
Vandetanib Caprelsa® 17/02/2012 Thyroid
Vemurafenib Zelboraf® 17/02/2012 Skin
Vinflunine Javlor® 21/09/2009 Urothelial tract
Vismodegib Erivedge® 12/07/2013 Basal cells
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advanced basal cell carcinoma and for which no clinically
appropriate comparator was available, got scored with a sub-
stantial SMR and an ASMR IV in 2013 despite filling a single
arm phase II study.
Double-blind design was preferred by the CT when possi-
ble. For example, in its opinion released in 2013 on axitinib,
indicated in advanced renal cell carcinoma, the CT pointed out
the risk of bias of the open design of the study while a blinded
study would have been feasible. This drug has been granted a
substantial SMR and an ASMR IV. Moreover, open-label
study designs are highly scrutinised by the CT as seen with
catumaxomab, indicated in intraperitoneal treatment of malig-
nant ascites, where standard therapy is not available or is no
longer feasible.
The treatment regimen choice is also an important factor in
the CT decisions as illustrated with the case of afatinib, indi-
cated in non-small cell lung cancer. In its assessment in 2014,
the CT highlighted that, in the pivotal study versus chemo-
therapy, the duration of treatment in the comparator arm has
been limited to six cycles, while the afatinib group has been
treated until disease progression or death. The drug got a sub-
stantial SMR and an ASMRV.
Post-hoc analyses were usually rejected by the CT. In the
assessment of degarelix in 2009, indicated in advanced
hormone-dependant prostate cancer, the committee did not
consider the results of a post-hoc analysis of PFS. In the as-
sessment in 2012 of tegafur/gimeracil/oteracil, indicated in
advanced gastric cancer, the investigation of non-inferiority
of tegafur/gimeracil/oteracil in an analysis that was not
planned for in the protocol was not accepted by the CT.
Even if the study ended prematurely for positive results,
upon a request of an independent review board, PFS and OS
results were highly scrutinised. Two good examples of this are
everolimus, indicated in advanced renal cell carcinoma and
abiraterone acetate, indicated in metastatic castration-
resistant prostate cancer.
Everolimus obtained a substantial SMR and an ASMR IV
for a first assessment in 2010. This decision was made by the
CT despite the absence of a clinically relevant comparator and
the decision of an independent review board to prematurely
end the study following benefit shown at interim analysis on
PFS (primary endpoint), which was prolonged by 3 months in
comparison with placebo. The CT pointed out that this differ-
ence was probably overestimated as the trial stopped during
Fig. 2 Drugs characteristics:
tumour type (a), number of
indication (b), administration
mode (c), pharmacological class
(d). Note: Data reported for 31
drugs indicated in solid tumours
having centralized EU
authorisation, 2009-2014. *1 drug
targeting 3 types of cancer and 1
drug targeting 2 types of cancer
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the interim analysis. At this stopping point, median OS, ob-
jective response percentage and quality of life did not reach
the required level of significance and the patients of the pla-
cebo group were switched to everolimus.
The case of abiraterone acetate is very similar. This drug
obtained a substantial SMR and an ASMR IV after a request
for extension of indication in 2013. Also, in this case, no
clinically relevant comparator was available and the study
prematurely ended based on the decision of the independent
review board following benefit shown at interim analysis on
radiological PFS (joint primary endpoint with OS) (gain of
8.2 months versus placebo) and on secondary endpoints.
The CT opinion was that the expected impact on mortality
reduction is not appreciable given that the median OS did
not reach the required level of significance at that stopping
point.
Orphan drugs were also asked to meet the requirements of
the CT regarding the adequacy and relevance of the study
methodology. For instance, the SMR of mifamurtide, an or-
phan drug indicated in osteosarcoma, was assessed as insuffi-
cient by the CT in 2010. The committee considered that the
study presented some issues, related to the trial design, the
statistical methodology and to the conduct of the study, which
prevented the evaluation of the drug’s effect size and place in
osteosarcoma treatment.
3.3.2 Acceptance of Progression-Free Survival (PFS)
as a Valuable Endpoint, While Overall Survival Remains
a Key Endpoint
OS and PFS represented the main primary efficacy endpoints
in 86 % of cases.
Improvement in OS by 3 months or more versus compar-
ator may lead to a substantial SMR and a high ASMR. For
trastuzumab emanstine, indicated in breast cancer, a substan-
tial SMR and an ASMR II were granted, driven by an im-
provement in the OS (5.8 month), and in the PFS (3.2 months)
versus relevant comparator. However, the result analysis
showed that an ASMR III might be granted even if no signif-
icant results were found for OS (Fig. 6), despite the lack of
statistical benefit in OS was the reason to reject the additional
benefit in other cases (e.g. cases of abiraterone acetate and
everolimus described above).
PFS may be considered a valuable primary endpoint. If the
drug use leads to a gain of 3 months or more in the PFS
without increasing the OS, it can be awarded an ASMR IV
or even III; however, additional criteria might weigh in the
decision.
For example, in the case of vandetanib, indicated in med-
ullary thyroid cancer, the results of the study showed an im-
provement of the PFS (primary endpoint) of 11 months versus
placebo with no improvement in OS or quality of life. Van-
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2012. The CT might have considered other criteria in its de-
cision: the lack of approved alternative therapies available;
however it was shown to induce adverse events and especially
cardiac toxicity.
Another example is crizotinib, indicated in non-small cell
lung cancer (NSCLC). In 2013, this drug was granted a sub-
stantial SMR and an ASMR III with a median PFS gain of
4.7 months versus standard chemotherapy and no improve-
ment in OS. However, other criteria might have weighted in
the decision, i.e. the high objective response rate obtained
during the study (65.3 % vs. 19.5 % in comparator arm), the
fact that crizotinib was the first second line treatment for se-
lective subtypes of advanced NSCLC (ALK+mutation)
which is a serious and life-threatening condition, and that this
drug might represent an oral alternative to the intravenous
chemotherapy.
3.3.3 Importance of Transferability of Clinical Trials
in Clinical Practice
The CT can be very cautious with transferability to real life of
clinical data.
Inclusion/exclusion criteria of clinical trials may be
reflected in the population recommended for reimbursement
or influence the CT opinion.
For instance, ipilimumab, indicated in advanced melano-
ma, was initially scored with a substantial SMR and anASMR
IV. In a request for re-assessment based on new available data
in 2013, the company has failed to get the claimed ASMR III.
The CT highlighted that new data provided did not assess the
effectiveness of ipilimumab in patients with failure to
vemurafenib, a drug approved in 2012, so they could not
assess the value of ipilimumab in this population.
In the case of gefitinib, indicated in non-small cell lung
cancer, assessed in 2009, the CT highlighted that the transfer-
ability to current practice was not guaranteed due to the profile
of included patients, most of whom being of Asian phenotype.
Regorafenib, indicated in metastatic colorectal cancer, has
not been recommended for reimbursement by the CT in one
subgroup of patients with a performance status score (ECOG)
superior to 1, as one of the inclusion criteria of the submitted
study was an ECOG performance status inferior or equal to 1.
Transferability in terms of standard of care is also one of the
criteria taken into account. For example, for aflibercept, indi-
cated in metastatic colorectal cancer, the CT highlighted in its
assessment in 2013 that the transferability to current practice
was not guaranteed due to the absence of clinical data on the
comparison of aflibercept in combination, versus
bevacizumab in combination. The drugwas granted a substan-
tial SMR and an ASMRV.
Fig. 3 ASMR/SMR ratings.
Note: Data reported for initial CT
assessment (26 drugs indicated in
solid tumours, 2009-2014). *1
drug with 2 ASMR and 1 drug
with 2 SMR depending on
subgroup
Fig. 4 ATU status and ASMR ratings. Data reported for initial CT
assessment (26 drugs indicated in solid tumours, 2009-2014). * One
product with two ASMR, reported two times
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Another example is ipilimumab, indicated in previously
treated advanced melanoma. This drug was granted a substan-
tial SMR and an ASMR IV in 2011 despite the absence of
approved treatments (drugs used off-label) and a gain of
3.68 months in median OS versus active comparator. The
CT criticized the choice of the comparator, gp100, a product
with no MA and not available on the French market.
Uncertainty on the drug safety can negatively impact the
CT decision. For instance, for vismodegib, indicated in basal
cell carcinoma, the CT highlighted in its 2013 opinion that the
transferability of the study results to clinical practice was not
guaranteed owing to the existing uncertainty in terms of safety
(infectious, cardiovascular, neurologic and teratogenic). The
drug was granted a substantial SMR and an ASMR IV.
The transferability of study results can be questioned if the
study duration is not adequate. In 2009, the CT granted a
substantial SMR and an ASMR V to degarelix, indicated in
advanced hormone-dependant prostate cancer. The CT
highlighted that the limited duration of the study
(12 months) leads to uncertainty on the transferability to clin-
ical practice.
3.3.4 Unpredictability of CT Decisions
While the CTsets high-level requirements for drug assessment
in terms of methodological quality and expected outcomes, it
may also provide unpredictable opinions, taking into account
a vast array of contextual elements.
Reimbursement might be granted with studies versus pla-
cebo while pertinent comparators exist. This was the case for
radiumRa223 dichloride, indicated in treatment of adults with
castration-resistant prostate cancer. In 2014, this drug was
granted a substantial SMR and an ASMR IV with placebo
controlled evidence while three comparative therapies were
available: two radiopharmaceuticals and abiraterone acetate
assessed by the CT in 2012. The CT highlighted that the
choice of placebo could be discussed due to the existence of
these therapies.
The case of axitinib, indicated in advanced renal cell carci-
noma after failure of prior treatment with sunitinib or a cyto-
kine, illustrates that the CT might grant an ASMR on the
overall study population despite the fact that the comparator
had not a MA in one of the subgroups and that the study
Fig. 5 Efficacy/safety ratio and
SMR (a) and ASMR ratings (b).
Note: Data reported for initial CT
assessment (26 drugs indicated in
solid tumours, 2009-2014)/ 1
drug with 2 ASMR and 1 drug
with 2 SMR depending on
subgroup
Fig. 6 OS results and ASMR.
*OS as primary or secondary
endpoint. Note: Data reported for
initial CT assessment (26 drugs
indicated in solid tumours, 2009-
2014). Negative OS results = non
significant results were found on
OS. Positive OS
results = significant results were
found for OS
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results differed between subgroups. Axitinib was granted a
substantial SMR and ASMR IV in 2013 versus sorafenib,
the active comparator used in the pivotal study. The results
of this study showed a gain of 2 months in median PFS with
axitinib versus active comparator in the overall study popula-
tion— which was considered as modest— and no difference
in OS. The study showed a gain of 5.6 months in median PFS
with axitinib versus active comparator in the subgroup of pa-
tients after failure or prior treatment with cytokine, and of
1.4 months in the subgroup of patients after failure or prior
treatment with sunitinib. The CT pointed out some methodo-
logical weaknesses in the study, i.e. open design, sample size
adjustment during the study, comparator used with only a MA
after failure of prior treatment with cytokine (rarely used in
first-line in clinical practice); therefore, the comparison with
this drug did not allow the evaluation of the therapeutic benefit
of axitinib as second-line treatment after the failure of suniti-
nib (main first-line treatment in clinical practice).
In 2013, pazopanib was scored with a low SMR and an
ASMRV during a new assessment as a first-line treatment for
advanced renal cell carcinoma, after it was decided in 2010
that the clinical benefit of this drug was insufficient. The CT
changed its decision following new data submission even if
doubts remained on the non-inferiority to the comparator and
that alternative medicinal products existed:
– the non-inferiority results were not confirmed as the sen-
sitivity analysis (performed in the per-protocol popula-
tion) did not corroborate the non-inferiority results found
in the intention-to-treat population,
– the clinical significance of the non-inferiority threshold
defined in the protocol was considered too large (reduc-
tion in efficacy of 2.2 months’ PFS),
– the acceptable reduction in efficacy in this study was not
counterbalanced by a gain, such as safety.
The case of aflibercept indicated in metastatic colorectal
cancer, shows the inconsistency between the clinical data pro-
vided and the opinion issued by the CT in 2013. Aflibercept
showed a modest efficacy with a gain of 1.44 months in me-
dian OS and of 2.23 months in median PFS versus placebo. In
addition, the drug had safety issues which led patients to dis-
continue the treatment because of adverse events twice as
frequent as with placebo (26.8 % versus 12.1 %). Despite all
these weaknesses, the efficacy/adverse effects ratio was con-
sidered as high by the CT and the drug got scored with a
substantial SMR and an ASMRV.
3.4 Outputs of the Expert Board Meeting
Many issues related to current and future trends in HTA of
oncology drugs in France emerged during the meeting and are
described below.
3.4.1 Considerations for the Clinical Development
Targeted Therapies The experts pointed out the important
development of personalized medicine in oncology during
the last decade. Targeted therapies acting on specific molecu-
lar targets are based on drug/diagnostic test associations which
help to identify and select patients who are more prone to
respond to the treatment, so as to treat only the subpopulation
that will benefit from it, therefore increasing treatment effica-
cy and reducing patient exposure to potential side effects/
toxicity.
From the experts’ point of view, tailored therapies raise many
challenges in terms of strategic positioning, ethics and clinical
trial design.
Strategic Positioning and Ethics Targeted therapies are de-
signed and prescribed for appropriate target patients identified
by their status for a specific marker. The targeted therapies
may present different levels of benefit in different populations,
i.e. very significant added value in small populations and sig-
nificant added value in larger populations. In that case, two
strategic positioning options can be considered: the manufac-
turer can choose either to enter a niche market first, and then to
file for extensions of indications, or to enter a large market
directly. The experts stressed that if the first option is consid-
ered, this could raise ethical concerns as it prevents access to a
larger population who might benefit from the product too.
The strategic positioning choice may be in the future chal-
lenged by the CT and potential for future extensions of indi-
cations will be taken into account in the CT decision. The CT
may in the future request studies in a broader population to
assess the differential benefit in a restricted population.
Clinical Trial Design Increasingly breakthrough therapies
will reach the market with little evidence and a very high
estimate benefit and high uncertainty putting HTA and payers
in front of a complex dilemma. The experts highlighted the
importance of ATUs as a source to generate data to support
application at time of HTA as well as a lever for pricing ne-
gotiation. The experts estimated that coverage with evidence
development (with or without an escrow agreement) might be
more and more considered to manage this uncertainty.
Regarding the companion diagnostic test, the experts
highlighted that validation methods of these tests will add
burden for the development of targeted therapies. In the guid-
ance entitled BCompanion diagnostic test associated with a
targeted therapy: definitions and assessment method^ [29],
the HAS presented its principles to assess the clinical utility
diagnostic tests associated with treatments. The HAS requires
a design to demonstrate at the same time that the treatment is
effective in positive biomarker patients and has no clinical
benefit in negative biomarker patients. Moreover, the experts
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noticed that companion tests are managed by the molecular
genetic tests developed by the French National Cancer Insti-
tute (INCa) platform outside of the commercial ones provided
by manufacturers, a typical French specificity. However, in
the future, such guidelines might be obsolete. An expected
major change in the paradigm may be the use of biomarkers
as one piece of information among a broad range of genomic
tests making unavoidable the use of algorithms for deciding
on the optimal chemotherapy.
Experts underlined that targeted therapies showed impor-
tant benefit on OS but this outcome would be more and more
complex to assess due to increased survival in oncology in
general. The experts emphasized the importance to robustly
validate PFS as a predictor of OS.
They also pointed out to the fact that clinical trials would
increasingly include crossover in their design. The HAS will
likely be late in adopting statistical models for adjusting for
cross over as the CT is still very clinically oriented and resis-
tant to innovative statistical methodologies, as already seen for
network meta-analyses for example.
Methodological Considerations The development of drugs
is rapidly evolving making the choice of the comparator used
in clinical trials outdated at the time of assessment. In this
environment, the experts stressed the increasing importance
of indirect comparisons. To enable indirect comparison, the
design of clinical studies will have to allow matching similar
inclusion/exclusion criteria, endpoints, duration, etc.; even if
they are not the one considered for the primary endpoint of
that study. This would enable performing high quality indirect
comparisons.
The experts expected in the future that life extension of at
least 3 months with evidence of maintained or improved qual-
ity of life will be required. Consistency of primary and sec-
ondary endpoints will be important.
3.4.2 Transferability and Generalisability
The experts highlighted the increasing scrutiny for jurisdic-
tional and clinical routine practice transferability of clinical
trials. It is expected to become one of the most complex issues
to address in the future for applicants to the HAS, and espe-
cially when important differences in availability of treatment
and practice across jurisdictions exist.
The experts pointed out that in the years to come, MAwill
be more and more based on phase 2 studies with well charac-
terized populations. To manage uncertainty, the experts esti-
mated that a growing number of real-life studies with specific
objectives will be required in the future. Real-life studies will
most probably involve studies on effectiveness and drug usage
(e.g. dose, treatment duration, starting/stopping rules and tar-
get population). They also stressed the importance to follow
patients from ATU cohorts after MA to collect real-life data to
address HTA requirements.
3.4.3 Health Economic Assessment
Health economic assessment is still immature in France and
will continue to develop. Methodological requirements are
expected to increase in the coming years.
Cost per QALY is definitely accepted as the reference end-
point, and an unofficial post-hoc incremental cost-
effectiveness ratio (ICER) threshold would likely be
established based on experience.
Models are expected to be simple robust and straightfor-
ward. Markov model with three health states (progression,
free progression and death) is expected to remain the reference
in oncology.
3.4.4 New Approaches in Drug Assessment
In March 2014, the EMA initiated a pilot project on adaptive
licensing. However, from the experts’ opinion, it is very un-
likely to affect market access in the short term. The apparent
complexity of the methodology and the strong reliance on
deterministic statistics of the CTmay create additional hurdles
for access to these products in France. Since 2011, a reform of
drug assessment is under discussion within the HAS to replace
the SMR/ASMR by a new therapeutic index: Index
Thérapeutique Relatif, ITR. However, the experts considered
that ITR was far to be implemented. The General Inspectorate
of Social Affairs (Inspection Générale des Affaires Sociales,
IGAS) report related to ITR implementation considered that
although a change is requested, ITRwas not ready to take over
and still needed some maturation and adjustment [30].
4 Discussion
4.1 Health Technology Assessment Trends in France
In France, the CTopinion is one of the main drivers for pricing
and reimbursement of medicines. One of the French philo-
sophical concepts is to enable access to the most effective
care, including medicines, for all patients across the territory.
As a Bismarck-type social security system, French healthcare
system principles are to grant the same level of healthcare
access to the whole population through contribution and re-
distribution [31]. Especially in the field of oncology products,
the primary aim of the Cancer Plan 2014-2019 is Bto cure
more patients, by promoting early diagnosis and guaranteeing
access to all to innovations^ [20].
In a cost-constrained environment, the CT has a moral re-
sponsibility to guarantee the sustainability of the national
health insurance system while making its decisions although
530 Targ Oncol (2016) 11:515–534
it is not its mandate. Moreover, informal interactions are seen
between the CT and the pricing Committee (CEPS). In this
context, CT requirements are evolving with stricter rules.
First, an increasing number of products targeting severe con-
ditions are denied reimbursement. The SMR score is increas-
ingly driven by the drug benefit-risk ratio and the existence of
therapeutic alternatives, while disease severity is less consid-
ered [28]. Then, if different decision criteria to acknowledge
or not an innovative product are not new, an increasing request
for robust evidence in terms of study methodology is ob-
served. Moreover, transferability of clinical data to real-life
settings is becoming critical for the CT, with an increasing
demand for these data conditioning price and reimbursement
decisions (in terms of conditions of use, effectiveness, ICER
in real life, safety and tolerability, use of healthcare resources).
The impact on the healthcare organization is also more and
more important in the whole decision process. Finally, even if
CT assessments are only based on clinical criteria, concomi-
tant filing of dossier at the CT and the CEPS, and considering
informal communication between both committees, the CT
might have access to the price submitted by the company
influencing its decision.
Driven by budget constraint, there has been an increase in
government control and regulation as seen with the introduc-
tion of health economic assessment of health products in
France in 2012 [32]. However, health economic assessment
has not been designed as a tool to manage the economic con-
straint, but as a decision-making support tool limited to price
negotiations, demonstrating the French government’s willing-
ness to prevent health economic criteria to drive reimburse-
ment [31].
HTA in France is mainly based on clinical assessment as
drugs with an ASMR IVor V represent the majority of drug
assessed by the CT and are not supposed to be eligible for
health economic assessment (For example, in 2013, for a first
drug assessment, 1 ASMR I, 0 ASMR II and 8 ASMR III were
granted for 10 ASMR IV and 148 ASMRV [33]). However,
some of these drugs for which the manufacturer would claim
an ASMR II or III, will be eligible for health economic assess-
ment but this assessment should not have any impact on pric-
ing decision as these drugs are not expected to have an impact
on the pharmaceutical budget according to French regulation
[34].
In the future, it is expected that pricing and reimbursement
decisions will likely be more and more driven by budget con-
straint rather than by existing rules. There is a shift towards a
rather reactive than proactive system in which ad hoc policy
decisions are taken on a case-by-case basis. As it has been
initiated with the Solvadi® (sofosbuvir) case, the experts ex-
pect an increasing cross-countries payers’ collaboration to
manage healthcare budget pressure and intervention of parlia-
ment to contain a budget for a specific drug or therapeutic
class.
The unpredictability of CT decisions is mainly driven
by two motives. First, the multiplicity of factors affecting
a decision makes it difficult to appreciate, in the absence
of a clear reference case, the role of one factor such as OS
or PFS from the others, even if they are considered as
predominant in impacting the scoring. Then, the fact that
decision and appraisal are not dissociated in France like in
the UK makes it difficult to separate the facts from the
judgement. The judgement is deliberative and therefore
not accessible if you do not participate in the CT. Sepa-
rating the assessment from the appraisal would enhance
decision transparency.
4.2 Challenges for Oncology Products to Provide
Appropriate Evidence
The development of new oncology therapies is facingmultiple
challenges to generate information expected from the HTA
perspective.
First, the progress in cancer led to longer survival times,
making OS a difficult endpoint to reach. If PFS, used as a
surrogate measure in an increasing number of clinical studies
for patients with advanced solid tumours, is currently accepted
by the CT [35], OS remains a key endpoint for decision-mak-
ing. Providing quality of life on top of life extension is also
becoming critical information to allow ensuring that at least
quality of life is not degraded even if not necessarily improved
as it is a progressive condition.
Then, patient crossover, i.e. switching from reference arm
to active arm is often an issue in oncology trials, as it may
happen before OS is reached leaving the pivotal endpoint not
available. Several statistical methods for adjusting for cross-
over were developed [36]. The experience shows that France
is reluctant to these types of models and takes few consider-
ations of such models in its decision-making.
Another challenge is the fast development of available ther-
apeutic alternatives, often making obsolete the development
of the comparator used in the development program of the
drug. It will make it unavoidable for the CT to accept indirect
comparisons.
Finally, drug development in oncology benefits from mo-
lecular genetics. Biomarkers allow selecting patient groups
susceptible to respond to a given therapy. For one specific type
of cancer, molecular subsets of cancers can be identified [37]
which might be classified as Brare cancers^. Therefore, the
development of biomarkers and associated therapies require
rethinking the design of clinical trials to demonstrate the clin-
ical utility of the biomarker. However, such studies might be
difficult to implement if the biomarker identification arrives
late in the development process (sometimes not before the
phase III clinical trial results), and also due to the ethical issues
raised of testing biomarker in negative patients, for a therapy
that may not benefit them [38].
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The development of hundreds of genomic markers in rou-
tine practice, will lead to new ways of treating oncology pa-
tients. In the future, the value, indication, usage and position-
ing of oncology products may change fast many times over
the product life-cycle and this will also concern off-patent
products making it increasingly complex to appreciate the
value of new therapies at time of launch.
New targeted therapies may, in some cases, provide large
benefit in small trials leading to early approval with very limited
evidence not always compatible with HTA bodies’ expecta-
tions. Indeed, added value assessment will no longer be sup-
ported by conventional and adequately powered randomized
controlled trials and uncertainty will need to be addressed
post-launch [39]. The recent international concept of Badaptive
pathways^ defined as a prospective planned and flexible ap-
proach to licensing and coverage of drugs and learning from
real-world data, is expected to be the only viable access route for
such therapies [39]. In this context, managed entry agreements
and especially coverage with evidence development schemes,
as well as drug price conditionality are expected to increase in
the years to come to minimize payers’ uncertainty while
allowing access to new therapies.More coordination is expected
between the European regulators and payers for evidence gen-
eration, and the process is already on going with early dialogues
initiated between the European Medicines Agency and the Eu-
ropean network for HTA (EUnetHTA). It will become very
important for companies developing new drugs in oncology to
address the cross jurisdiction transferability as well as the trans-
ferability to the real world of the clinical trials outcomes.
Moreover, new types of clinical trials are emerging in France,
known as clinical trials using genomic profiling (e.g. AcSé pro-
gram [40]2, or SAFIR program [41]3). These innovative trials
imply new methodologies, such as integrated protocols (several
phases in only one trial), use and comparisons of several treat-
ments without MA, new endpoints as the percentage of com-
plete remission and adaptive designs [42]. There is a common
willingness of all actors in the oncology field to sustain innova-
tion as seen with increasing private and public partnerships.
4.3 Accessibility of Oncology Products in France
In France, the accessibility of oncology products remains high as
most innovative products reach the market at negotiated condi-
tion agreeable for both payers and industry. The funding on top
of DRG was an incentive for hospitals to widely use innovative
products. Indeed, if the hospital buys medicines at a lower price
than the declared price, the price difference will be shared be-
tween sickness funds and the hospital [43]. This incentive was
decreased with the social security funding law for 2015 (de-
crease of some DRG in case of concomitant prescription of
medicines of « Liste en sus ») [44]. Even if hospitals are request-
ed to evidence proper use of such products, it remains almost
unrestricted for hospitals to use innovative oncology products.
HTA does not appear in France as a tool to restrict the
access of oncology products but may significantly affect the
net price reachable by industry explaining the potential delay
in pricing negotiations.
5 Conclusion
The French system remains committed to its values and phi-
losophy (access of all innovations for everybody) which are
threatened by the increasing launch of innovative therapies
and the budget constraint. To counteract these threats, the
CT has systematically increased its level of requirements to
acknowledge innovation. French lawmakers sharing the same
concerns, introduced health economic assessments. The on-
cology area is one of the main fields of interest in research and
development with a significant number of innovative thera-
pies expected to reach the market in the years to come. These
products are expected to bring an increasing added value by
targeting very specific populations and to change the standard
clinical development of oncology medicines. To face chal-
lenges in the field of oncology products, the current French
HTA process should evolve to enable a more specific ap-
proach of this very innovative therapeutic area. Without the
development of new considerations for the oncology field
(such as uncertainty management), the current HTA process
in France may become disconnected from reality and lead to
delay in access of new innovative therapies. Both HTA deci-
sion framework evolution and revision of the current pricing
process should be considered in France to cope with these new
challenges. However, although HTA impacts net prices of
oncology products, it has limited impact on patient access.
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